Subscribe

William Chou, MD

Articles by William Chou, MD

William Chou, MD, president and chief executive officer of Passage Bio

Targeting Progranulin With Gene Therapy for Frontotemporal Dementia

ByWilliam Chou, MD,Noah Stansfield

October 31st 2024

William Chou, MD, president and chief executive officer of Passage Bio, discussed feedback from a recent Type C meeting with the FDA.

William Chou, MD, president and chief executive officer of Passage Bio

Expanding Frontotemporal Dementia Gene Therapy to Both GRN and C9orf72 Mutations

ByWilliam Chou, MD,Noah Stansfield

October 27th 2024

William Chou, MD, president and chief executive officer of Passage Bio, discussed feedback from a recent Type C meeting with the FDA.

William Chou, MD, on Targeting Progranulin With Gene Therapy for Frontotemporal Dementia

William Chou, MD, on Targeting Progranulin With Gene Therapy for Frontotemporal Dementia

ByWilliam Chou, MD,Victoria Johnson

August 12th 2024

The president and chief executive officer of Passage Bio discussed feedback from a recent Type C meeting with the FDA.

William Chou, MD, on Expanding Frontotemporal Dementia Gene Therapy to Both GRN and C9orf72 Mutations

William Chou, MD, on Expanding Frontotemporal Dementia Gene Therapy to Both GRN and C9orf72 Mutations

ByWilliam Chou, MD

August 4th 2024

The president and chief executive officer of Passage Bio discussed feedback from a recent Type C meeting with the FDA.

Latest Updated Articles

Targeting Progranulin With Gene Therapy for Frontotemporal Dementia
October 31st 2024
Expanding Frontotemporal Dementia Gene Therapy to Both GRN and C9orf72 Mutations
October 27th 2024

Trending on CGTlive®

FDA Approves Tregzi for Matched Donor HSCT in Hematologic Malignancies